In recent years, Hangzhou has made significant progress in the biopharmaceutical industry by planning its layout.

At present, a spatial plan of "one core, four parks, and multiple points" has been formed: Qiantang District is laying out the entire biopharmaceutical industry chain; The High tech Zone (Binjiang) focuses on developing high-end medical devices and innovative drug research and development; Xiaoshan District focuses on developing fields such as biopharmaceutical CDMO, high-end medical devices, and digital healthcare; Yuhang District focuses on developing medical devices, innovative pharmaceuticals, AI healthcare and other fields; Linping District focuses on developing medical devices, innovative pharmaceuticals, and other fields; Lin'an District takes Tianmu Pharmaceutical Port as its core, targeting projects such as characteristic raw materials, key chemical drugs, and biotechnology drugs, and promoting the development of biopharmaceutical characteristics.

The deep integration of hospitals and enterprises, building a powerful engine of "talent+technology+capital".

At the "Tianmu Lunjian" 2023 Medical and Health Development Forum and the first Hangzhou Health Technology Achievement Exhibition and Innovation Transformation Competition on April 14th, the phased achievements of the integration of medical and enterprise development were fully demonstrated.

For example, the biodegradable biliary stent jointly developed by Hangzhou First People's Hospital and Hangzhou Medical Technology Co., Ltd. has good biocompatibility and no foreign body sensation.

For example, a ureteral stent tube and its removal device developed jointly by Hangzhou Traditional Chinese Medicine Hospital and a Zhejiang Technology Co., Ltd. that can be removed without the use of endoscopy.

For example, the digital brain platform for adolescent mental health jointly developed by Hangzhou Seventh People's Hospital and a company in Shanghai.

These achievements cover various aspects such as medical equipment, diagnosis and treatment technology, clinical research, and nursing.

Meanwhile, an important aspect of the event is the establishment of the Lin'an Life and Health Industry Fund. The fund has a scale of 300 million yuan and is fully invested in biopharmaceutical enterprises registered in Lin'an District to solve their practical difficulties. At present, preliminary negotiations have been made with more than 10 enterprises, and it is expected to complete the fundraising in September and officially invest abroad.

This event also launched discussions on "Development Planning and Pathways for the Biomedical Industry" and "Innovation and Exploration of Medical Achievement Transformation Models". More than 300 experts and scholars from industry related institutions engaged in enthusiastic exchanges through various forms such as round tables, special lectures, and innovative project negotiations.

The Hangzhou Municipal Health Commission will accelerate the construction of a life and health science and technology innovation highland and create a global advanced manufacturing base, solidly promote the construction of a demonstration zone for common prosperity through high-quality development, promote the high-quality development of the biopharmaceutical industry, and showcase the "rule of China" through the "window of the city".

In addition, the Municipal Health Commission announced the establishment of the Hangzhou Biomedical Industry Innovation and Transformation Alliance for this event, with 10 units from municipal hospitals, universities in Hangzhou, CRO companies, biopharmaceutical enterprises, and social capital becoming the first batch of alliance units. The alliance will play a positive role in promoting the synergy of the biopharmaceutical industry chain and achieving industrial innovation and upgrading in Hangzhou.